Back to Search Start Over

Specific IgE Response and Omalizumab Responsiveness in Severe Allergic Asthma

Authors :
Tajiri,Tomoko
Suzuki,Motohiko
Kutsuna,Takeo
Nishiyama,Hirono
Ito,Keima
Takeda,Norihisa
Fukumitsu,Kensuke
Kanemitsu,Yoshihiro
Fukuda,Satoshi
Umemura,Takehiro
Ohkubo,Hirotsugu
Maeno,Ken
Ito,Yutaka
Oguri,Tetsuya
Takemura,Masaya
Yoshikawa,Kosho
Niimi,Akio
Tajiri,Tomoko
Suzuki,Motohiko
Kutsuna,Takeo
Nishiyama,Hirono
Ito,Keima
Takeda,Norihisa
Fukumitsu,Kensuke
Kanemitsu,Yoshihiro
Fukuda,Satoshi
Umemura,Takehiro
Ohkubo,Hirotsugu
Maeno,Ken
Ito,Yutaka
Oguri,Tetsuya
Takemura,Masaya
Yoshikawa,Kosho
Niimi,Akio
Publication Year :
2023

Abstract

Tomoko Tajiri,1 Motohiko Suzuki,2,3 Takeo Kutsuna,4 Hirono Nishiyama,1 Keima Ito,1 Norihisa Takeda,1 Kensuke Fukumitsu,1 Yoshihiro Kanemitsu,1 Satoshi Fukuda,1 Takehiro Umemura,1 Hirotsugu Ohkubo,1 Ken Maeno,1 Yutaka Ito,1 Tetsuya Oguri,1 Masaya Takemura,1 Kosho Yoshikawa,4 Akio Niimi1 1Department of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan; 2Department of Otorhinolaryngology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Aichi, Japan; 3Department of Otorhinolaryngology, Nagoya City East Medical Center, Nagoya, Aichi, Japan; 4Department of Respiratory Medicine, Daido Hospital, Nagoya, Aichi, JapanCorrespondence: Tomoko Tajiri, Department of Respiratory Medicine, Allergy and Clinical Immunology, Graduate School of Medical Sciences, Nagoya City University, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan, Tel +81-52-853-8216, Email tomokot@med.nagoya-cu.ac.jpObjective: Omalizumab has demonstrated clinical efficacy in patients with severe allergic asthma sensitized to perennial allergens and/or severe pollinosis through inhibition of IgE-dependent allergic response. When considering the “one airway, one disease” concept, sensitization to pollen could predict responsiveness to omalizumab. This study aimed to assess whether the pretreatment specific IgE response could be a predictor of responsiveness to omalizumab in severe allergic asthma sensitized to perennial allergens.Methods: In this retrospective study, 41 adult patients with severe allergic asthma sensitized to perennial allergens (27 females; mean age 59 years) who had completed 52-week omalizumab treatment were enrolled. The Global Evaluation of Treatment Effectiveness was performed, and demographic characteristics and the positive ratios of specific IgE responses classified into five subgroups (pollen, dust mite, house dust, mold, and animal dander) were compared between r

Details

Database :
OAIster
Notes :
text/html, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1363870699
Document Type :
Electronic Resource